Calcitonin News and Research

RSS

Calcitonin is a 32-amino acid linear polypeptide hormone that is produced in humans primarily by the parafollicular cells (also known as C-cells) of the thyroid, and in many other animals in the ultimobranchial body.

Unigene Laboratories selects UGP281 lead peptide from obesity program for development

Unigene Laboratories, Inc. (http://www.unigene.com) announced today that it has selected a lead peptide compound, designated UGP281, from its obesity program for development.

18 Dec 2009

DMC recommends Novartis and Nordic Bioscience to continue oral calcitonin Phase III studies

Unigene Laboratories, Inc. (http://www.unigene.com) announced that an independent Data Monitoring Committee (DMC) has recommended that Novartis and its partner Nordic Bioscience proceed as planned with their ongoing oral calcitonin Phase III studies for osteoporosis and osteoarthritis.

11 Dec 2009

DMC recommends Emisphere Technologies' to proceed with oral calcitonin trial for OP and OA

Emisphere Technologies, Inc. today announced that an independent Data Monitoring Committee (“DMC”) informed Novartis and its partner Nordic Bioscience about their recommendation to proceed with the Osteoporosis (“OP”) Phase 3 Study 2303 and the Osteoarthritis (“OA”) Phase 3 Study 2301 exploring the safety and efficacy of an oral formulation of salmon calcitonin to treat patients with osteoporosis and osteoarthritis of the knee.

10 Dec 2009

Unigene Laboratories announces reduction in workforce and operating expenses

Unigene Laboratories, Inc. has announced a restructuring plan that includes a reduction in workforce to improve operational efficiencies and to better match resources with market demand and the Company’s strategic objectives.

9 Dec 2009

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Emisphere Technologies, Inc. today announced financial and operational results for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

Tarsa Therapeutics receives license for Phase III oral calcitonin program

Unigene Laboratories, Inc. and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.

20 Oct 2009

Oral salmon calcitonin using absorption-enhancing Eligen Technology holds promise for osteoarthritis

Emisphere Technologies, Inc. announced study results in which twice-daily oral salmon calcitonin using Emisphere’s proprietary Eligen® Drug Delivery Technology significantly suppressed markers of cartilage and bone degradation versus placebo in men and women with osteoarthritis, the most common form of arthritis.

19 Oct 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

Validity of Unigene’s patent on Fortical confirmed by the court

Unigene Laboratories, Inc. has reported that the U.S. District Court, Southern District of New York, has confirmed the validity of Unigene’s patent on Fortical and issued an order permanently enjoining Apotex Inc. and Apotex Corp. from further infringement of the patent.

3 Sep 2009

Unigene Labs reports financial results for three months ended June 30, 2009

Revenue for the three months ended June 30, 2009 was $4,297,000, compared to $4,978,000 for the three months ended June 30, 2008. Revenue for both periods primarily consisted of Fortical sales and royalties, which were $3,807,000 for the three months ended June 30, 2009, and $4,110,000 for the three months ended June 30, 2008.

11 Aug 2009

Osteoporosis drugs may prevent future bone growth

Patients who start and eventually stop regimens of a common class of osteoporosis drugs called bisphosphonates may be unable to benefit from parathyroid hormone (PTH), which can rebuild bone mass lost due to advanced stage osteoporosis. PTH has been proven to increase the volume and strength of the honeycomb-like bone infrastructure, the inner mesh that begins to diminish in old age.

13 Nov 2008

Pain is not a symptom of arthritis, pain causes arthritis

Pain is more than a symptom of osteoarthritis, it is an inherent and damaging part of the disease itself, according to a study published today in journal Arthritis and Rheumatism.

29 Sep 2008

Hope on the horizon for migraine sufferers

A generation of anti-migraine drugs with fewer side effects than existing treatments could be available to sufferers within three years.

11 Jun 2008

Genta announces initial trial results for novel drug for bone disease

Genta Incorporated has announced the release of final results from the Company's Phase 1 clinical trial of G4544, a proprietary small molecule that is intended as a treatment for diseases associated with accelerated bone loss. Results showed that the drug was very well-tolerated, and that blood levels were achieved in a range that is known to be clinically bioactive. The data were featured in a poster session at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on Saturday, May 31, 2008.

2 Jun 2008

Effectiveness and risks of six bisphosphonates for osteoporosis

Many medications reduce the risk of bone fractures in people with osteoporosis, but the most commonly used drugs - bisphosphonates - have not been proven more effective than alternatives, according to a new report funded by the Agency for Healthcare Research and Quality (AHRQ), part of the U.S. Department of Health and Human Services.

18 Dec 2007

Genta and Emisphere Technologies file investigational new drug exemption

Genta Inc. and Emisphere Technologies, Inc. have jointly announced the submission of an Investigational New Drug Exemption (IND) to the Endocrinologic and Metabolic Drugs Division of the U.S. Food and Drug Administration (FDA) for a new drug known as G4544.

2 Aug 2007

Procalcitonin helps predict prognosis among those with peritonitis

Monitoring blood levels of a compound known as procalcitonin in patients with peritonitis (a serious intra-abdominal infection) could help identify patients at increased risk of organ failure and death, according to a report in the February issue of Archives of Surgery.

20 Feb 2007

Bone Medical completes first trial of oral parathyroid hormone product for treatment of osteoporosis

Bone Medical Ltd announced today the completion of a Phase I trial of its oral parathyroid hormone (PTH) product Perthoxal™ under development for the treatment of osteoporosis.

3 Jul 2005

New Calcitonin drug delivery research holds promise for osteoporosis sufferers

Calcitonin, a hormone that lowers calcium levels in the blood and prevents bone loss, has only been available in an injectable and nasally-administered format to date.

1 Jun 2005

Calcium crucial to benefits of osteoporosis drugs

Although an increasing number of people are taking powerful new prescription drugs to treat osteoporosis, chances are the majority of patients are not getting the greatest effect from these medicines because they do not have an adequate calcium and vitamin D intake, according to a paper published in the March 2005 issue of The Journal of Women's Health.

23 Mar 2005